PTCT Q3 2020 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$118M+65.8% YoY

Gross Profit

$114M96.1% margin

Operating Income

-$55M-46.6% margin

Net Income

-$70M-58.9% margin

EPS (Diluted)

$-1.03

QoQ Revenue Growth

+57.4%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$155,000

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.7B

Stockholders' Equity

$511M

Cash & Equivalents

$434M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$118M	$71M	+65.8%
Gross Profit	$114M	$68M	+66.3%
Operating Income	-$55M	-$60M	+8.8%
Net Income	-$70M	-$60M	-16.2%

Revenue Segments

Product

$83M70%

Grant And Collaboration

$35M30%

Royalty

$696,0001%